Voorbeelden van het gebruik van Belatacept in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
45 of 847 patients(5.3%) developed antibodies during treatment with belatacept.
are EBV seronegative or serostatus unknown should not receive belatacept see section 4.3.
A total of 250 subjects were randomised to 1 of 5 treatment groups 3 belatacept and 2 tacrolimus groups.
In rats, belatacept had no undesirable effects on male
NULOJIX contains the active substance belatacept which belongs to a group of medicines called immunosuppressants.
evaluated for tuberculosis and tested for latent infection prior to initiating belatacept.
There is a theoretical concern that treatment with belatacept might increase the risk of autoimmune processes see section 4.8.
The belatacept dosing used in this liver study was higher in all 3 belatacept arms than the belatacept dosing used in the Phase 2 and 3 renal transplant studies.
Tuberculosis was more frequently observed in patients receiving belatacept than ciclosporin in clinical studies see section 4.8.
It is not known whether belatacept, the active substance,
It is unknown whether belatacept is excreted in human milk see section 5.3.
As a result, belatacept blocks CD28 mediated co-stimulation of T cells inhibiting their activation.
The concentration of belatacept in the infusion should be between 2 mg and 10 mg belatacept per ml solution.
Non-melanoma skin cancers occurred less frequently with the belatacept LI regimen than with the ciclosporin or belatacept MI regimens.
At Year 3, the incidence of NODM was 8% with belatacept and 10% with ciclosporin.
The viral status was not determined in the belatacept study but, as this virus is prevalent in monkeys,
When belatacept was compared to placebo infusions, there were no differences in event rates placebo infusions were administered at Weeks 6 and 10 of the belatacept LI regimen to blind the MI and LI regimens.
The potential impact of pre-existing antibodies to belatacept should be taken into account when considering retreatment with belatacept following prolonged discontinuation,
so I expect that doctors will be more careful when prescribing belatacept in the first months after a kidney transplant.”.
reported adverse reactions(≥ 20%) among patients treated with both belatacept- based regimens(MI